Injection Volume and Tumour Coverage in EBC-46 Trials: Optimising Intratumoral Delivery

Intratumoral drug delivery presents unique pharmacological challenges that differ fundamentally from systemic administration. In EBC-46 (tigilanol tiglate) clinical trials, researchers have had to develop precise injection protocols that account for tumour size, morphology, and tissue density to ensure adequate drug distribution throughout the target lesion.

The Intratumoral Delivery Challenge

Unlike intravenous chemotherapy, which relies on systemic circulation to reach tumour tissue, intratumoral injection places the active compound directly into the lesion. This approach offers significant advantages — high local drug concentration with minimal systemic exposure — but requires careful calibration. As documented in the QBiotics clinical programme, injection volume must be proportional to tumour volume to ensure the drug reaches all viable tumour tissue rather than pooling in a single region.

The Phase I/II trials of tigilanol tiglate used imaging-guided injection protocols where clinicians mapped tumour dimensions before calculating the appropriate injection volume. Multi-point injection techniques — where the drug is delivered at several positions within the tumour rather than a single central bolus — were employed for larger lesions to improve spatial distribution.

Volume-Response Relationships

Clinical data from the QBiotics trials suggest a relationship between injection coverage and treatment response. Tumours that received more complete volumetric coverage showed higher rates of complete response, defined as total tumour elimination confirmed at follow-up. This finding aligns with the mechanism of action: since EBC-46 acts locally through PKC activation and vascular disruption, areas of the tumour that do not receive direct drug exposure may not undergo the same rapid necrosis.

Published results in oncology literature indicate that researchers used real-time ultrasound guidance in some cases to monitor drug distribution during injection, ensuring that the tigilanol tiglate solution reached the tumour periphery where actively dividing cells are typically concentrated.

Implications for Trial Design

The intratumoral delivery model has important implications for how EBC-46 trial results should be interpreted. Response rates are partly a function of injection technique and tumour accessibility — factors that introduce variability beyond the drug's intrinsic efficacy. Trial protocols have evolved to standardise injection procedures, reducing operator-dependent variation and improving the reliability of outcome data.

This is also why clinical trial eligibility criteria for tigilanol tiglate studies typically specify superficial or accessible tumours. Deep-seated or diffuse lesions present greater challenges for achieving complete volumetric coverage through direct injection.

From Injectable to Oral: A Different Delivery Question

The intratumoral delivery research provides valuable pharmacological data but represents a different product category from oral dietary supplements. Blushwood Health and similar supplement brands offer blushwood berry extract in oral formats (tinctures and capsules), where the delivery mechanism involves gastrointestinal absorption rather than direct injection. These are dietary supplements, not intended to replicate the pharmaceutical injection protocol.

Related Articles

Dose Escalation in EBC-46 Clinical Trials: How Researchers Determine Safe and Effective Concentrations

Tumour Volume Reduction Metrics in EBC-46 Trials: How Researchers Measure Treatment Response

References

1. QBiotics Group — Tigilanol Tiglate Clinical Programme.

2. The Lancet — Oncology Research.

3. ClinicalTrials.gov — Trial Registry.